Somagenetix, a Zurich, Switzerland-based biotech company developing gene therapy for phagocyte disorders, raised CHF10M in Series A funding.
The round was led by Vi Partners. Existing investors Schroders Capital, Zürcher Kantonalbank and Verve Ventures also participated.
The company intends to use the funds to advance its leading gene therapy-candidate, SGX-001.
Founded in 2019 as a spin-off of the University of Zurich (UZH) and led by CEO Dr. Andrin Oswald, Somagenetix is at the forefront of gene therapy innovation, focused on curing phagocyte disorders with a one-time treatment.
The funds will enable the company to advance its leading gene therapy-candidate, SGX-001, into a clinical trial for the treatment of p47 Chronic Granulomatous Disease (CGD). CGDs are a group of inherited immunodeficiencies with recurrent life-threatening infections. The condition is caused by genetic defects leading to functional impairments of phagocytes, a type of white blood cells, rendering them unable to kill pathogens. The current standard of care is stem cell transplant, which is only available upon finding an immunologically compatible donor. The preclinical development of p47-CGD gene therapy is currently supported by the Wyss Zurich Translational Center.
FinSMEs
09/10/2024